Why Glycan Testing Detects Aging Changes Months Before Epigenetic Clocks Do

Most biological age tests ask the same underlying question: is the body actually changing? The answer depends entirely on how fast the biomarker can register a shift. Glycans respond to biological changes within months — as fast as 3–4 months for pharmaceutical and hormonal interventions, and 6–12 months for lifestyle changes — while epigenetic markers typically shift over years or decades. This difference in responsiveness comes down to what each biomarker is actually measuring: a direct readout of chronic inflammation, one of the hallmarks of aging most consistently linked to disease risk, versus broader shifts in DNA methylation patterns.

Want the full picture? Read Biological Age Testing: The Complete Guide to Measuring How Fast You're Actually Aging for a complete breakdown of how glycan biomarkers work.

Why do epigenetic clocks change so slowly compared to glycan markers?

Epigenetic clocks measure DNA methylation, which is composed of chemical tags on the genome that accumulate over years or decades in response to gene expression patterns. Because these tags reflect a long historical average of gene activity, they are slow to shift even when meaningful biological change is happening right now.

Glycans, by contrast, are synthesized continuously by the body and reflect the current state of immune function and inflammation. Prof. Gordan Lauc, CSO and Co-Founder of GlycanAge, has explained that epigenetic markers tell you that something changed without clarifying why, establishing the functional relevance of any given epigenetic shift takes extensive follow-up study. Glycan changes, measured in months rather than years, give you a signal that is both biologically interpretable and actionable within a clinically relevant window.

How stable is GlycanAge compared to epigenetic clocks when nothing has changed?

GlycanAge repeat measurements in the same individual vary by approximately 1 year, while epigenetic clocks in the same individual can vary considerably even when no intervention or major health event has occurred. This difference was confirmed by the independent research group Alden Scientific. Their analysis found that GlycanAge's variation falls well below the threshold of any meaningful intervention. This means clinicians and clients can interpret a change in result as a real biological shift, rather than a laboratory artifact. In individuals with no major lifestyle or health changes, glycan traits remain stable over time; when meaningful physiological events occur, such as recovery from illness, weight loss, or initiation of stress-reducing practices, glycan markers shift in consistent, biologically plausible directions.

"There's no single biomarker that can function for everything, but glycans are predictive, they're responsive, they're stable. They are such a great indicator of inflammation and a very, very good biomarker of aging."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical

This balance of stability and responsiveness is what allows GlycanAge to filter out short-term noise while still detecting genuine biological change, typically within a 3–4 month retest window for pharmaceutical interventions or 6–12 months for lifestyle changes.

Why do glycans respond faster than epigenetic clocks but slower than blood tests?

Standard blood biomarkers, such as glucose, CRP, cholesterol, and hormones, change within minutes or hours, which makes them useful for acute monitoring but unable to capture the chronic, low-grade inflammation that drives biological aging. To understand why standard bloodwork misses chronic inflammation, it is important to recognize that these tests provide a snapshot of a single moment rather than a long-term trend. Epigenetic markers sit at the opposite extreme, shifting over years or decades and offering limited responsiveness to lifestyle interventions. Glycans occupy the middle ground: their composition changes on a timescale of months, making GlycanAge fast enough to validate whether an intervention is working and stable enough to distinguish real change from daily fluctuation. Prof. Lauc has described glycans as sitting between these fast-changing molecules and the genes that don't change at all, filling a gap that neither conventional blood panels nor epigenetic clocks can close on their own. This is why GlycanAge has been positioned as the aging clock most responsive to lifestyle and medical interventions, letting you track meaningful changes through time. For a closer look at how the two approaches compare directly, see our epigenetic vs. glycan clock comparison.

Can glycan testing detect changes that epigenetic clocks would miss entirely?

Glycan markers have been shown to change up to 10 years in advance of disease symptoms, providing a window for intervention that epigenetic clocks, with their slower response and higher measurement noise, cannot reliably offer. Because glycans integrate genetic, epigenetic, and environmental factors into a single measurable signal, they capture the cumulative effect of lifestyle, hormones, stress, and medical interventions in a way that neither genes nor methylation patterns alone can reflect.

"Original [genetic] risk, plus what we have done to ourselves in the last decade or so."

— Prof. Gordan Lauc, CSO and Co-Founder, GlycanAge

In practical terms, this means a meaningful pharmaceutical or hormonal intervention, such as HRT, can produce a detectable glycan shift within a single 3–4 month retest cycle, while lifestyle interventions such as weight loss or a structured exercise programme typically show effects over a 6–12 month cycle — timeframes in which the same intervention may produce no statistically interpretable signal in an epigenetic clock.

Why is it hard to act on epigenetic clock results after a lifestyle intervention?

Epigenetic clocks do not clearly identify which biological process is driving the changes they measure, making it difficult to derive specific actions from the results. When a methylation-based clock shifts, or fails to shift, after an intervention, it is not straightforward to determine whether the intervention worked, whether the measurement noise obscured a real effect, or whether the timescale was simply too short. GlycanAge measures chronic inflammation directly, which is one of the 12 official hallmarks of aging and the biological process most tightly linked to age-related disease. This mechanistic clarity means that when GlycanAge changes, the direction and magnitude of that change can be interpreted in terms of immune aging and acted on with a specific, evidence-based response.

How quickly can GlycanAge detect a response to a medical intervention like HRT or testosterone therapy?

GlycanAge is typically retested within a 3–4 month window to evaluate response to pharmaceutical or hormonal intervention. In a randomized controlled trial of European men aged 29–45, testosterone therapy produced significant changes in IgG glycosylation over a year of treatment, decreasing agalactosylation and increasing galactosylation and sialylation, while metformin showed no effect. These findings confirm that IgG glycans are modifiable by therapeutic intervention and that GlycanAge can track biological age and health status beyond chronological age.

"I would love to monitor my patients before they start HRT — we want to know how quickly we can reverse this pro-inflammation, because this inflammation is really crucial to our future health. Does it reverse quicker when we're younger? Does it take longer if we start HRT in our 70s? There are so many questions we don't know."

— Dr. Louise Newson, Newson Health

For clinicians titrating HRT or evaluating pharmacological protocols, this responsiveness makes GlycanAge a practical tool for confirming that a treatment is producing the intended biological effect within a clinically relevant retest interval, not just symptomatic relief.

Is GlycanAge measuring something fundamentally different from what epigenetic clocks measure?

Yes. Epigenetic clocks measure DNA methylation patterns (a proxy for historical gene expression), whereas GlycanAge measures IgG glycosylation, the active inflammatory biology operating right now. Glycans are synthesized through a process that integrates genetics, epigenetics, and environmental factors simultaneously, making them a richer signal than any single layer of biology can provide. As Prof. Lauc explains, glycans encode "original genetic risk plus what we have done to ourselves in the last decade or so", combining inherited predisposition with lived experience into a single quantifiable measure. This includes the impact of chronic psychological pressure, such as how stress ages the immune system through specific glycan patterns. The result is a biomarker that tells you not just where your biology has been, but where it is now and how fast it is moving. This information is directly relevant to the decisions you and your clinician make today.

If you want to know whether your current interventions are producing real biological change, not just a number that shifts with measurement noise, GlycanAge gives you one of the most responsive and reproducible aging biomarkers available. Order your at-home test kit and book your 1:1 Result Interpretation Call to see exactly where your immune age stands and what is driving it.

Order your GlycanAge test kit →

External sources

• https://pmc.ncbi.nlm.nih.gov/articles/PMC11979073/ — Effects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome, Vinicki, Martina, et al., GeroScience 47.2 (2025): 1777-1788

• https://pubmed.ncbi.nlm.nih.gov/36599349/ — Hallmarks of aging: An expanding universe, López-Otín, Carlos, et al., Cell 186.2 (2023): 243-278

• https://pmc.ncbi.nlm.nih.gov/articles/PMC11494675/ — Rapčan B, Song M, Frkatović-Hodžić A, Pribić T, Vuk J, Beletić A, Hanić M, Jurić J, Tominac P, Milas J, Ivić V, Viland S, Bonet S, Šego B, Heffer M, Wang W, Snyder MP, Lauc G. Glycan clock of ageing—analytical precision and time-dependent inter- and intra-individual variability. GeroScience. 2024;46(6):5781–5796.